US 5,434,151 A · Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase

Abstract

2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. A method to treat disorders mediated by PAF or leukotrienes is also disclosed, that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

Compounds of the formula:

##STR22## wherein:
wherein:
X is O, S, S(O), S(O).sub.2, CR.sup.9, or NR.sup.10 ;
W is independently:
(1) --AN(OM)C(O)N(R.sup.3)R.sup.4, --AN(R.sup.3)C(O)N(OM)R.sup.4, --AN(OM)C(O)R.sup.4, --AC(O)N(OM)R.sup.4, --N(OM)C(O)N(R.sup.3L )R.sup.4, --N(R.sup.3)C(O)N(OM)R.sup.4, --N(OM)C(O)R.sup.4, --C(O)N(OM)R.sup.4, --OR.sup.6 N(R.sup.5)R.sup.6 --(C.sub.5 H.sub.4 N)R.sup.6 R.sup.7, --OR.sup.6 N(COR.sup.5)R.sup.6 --(C.sub.5 H.sub.4 N)R.sup.6 R.sup.7, --OR.sup.6 OC(O)N(COR.sup.5)R.sup.6 --(C.sub.5 H.sub.4 N)R.sup.6 R.sup.7, --OR.sup.6 O(CO)N(CO.sub.2 R.sup.6)R.sup.6 (C.sub.5 H.sub.4 N)R.sup.6 R.sup.7, --A(C.sub.5 H.sub.4 N)R.sup.6 R.sup.7, or --OR.sup.6 N(CO.sub.2 R.sup.5)R.sup.6 --(C.sub.5 H.sub.4 N)R.sup.6 R.sup.7 ;
(2) an amidohydroxyurea of the formula:
--N(R.sup.19)C(O)C(R.sup.19)N(OM)C(O)NHR.sup.20, --C(O)N(R.sup.19)C(R.sup.19)N(OM)C(O)NHR.sup.20, --AN(R.sup.19)C(O)C(R.sup.19)N(OM)C(O)NHR.sup.20, --AC(O)N(R.sup.19)C(R.sup.19)N(OM)C(O)NHR.sup.20, --NHC(O)N(OM)C(R.sup.19)C(O)N(R.sup.19).sub.2 ;
or --NHC(O)N(OM)C(R.sup.19)N(R.sup.19)C(O)R.sup.19 ;
(3) an oxalkane of the structure:
##STR23## wherein n and m are independently 1-4;
(4) a thioalkane of the structure:
##STR24## or (5) a quinolylmethoxy of the structure:
##STR25## n is 1 or 2;
m is 1 or 2 or 3;
p is 0 or 1;
A is alkyl, alkenyl, alkynyl, alkyaryl, aralkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, --C.sub.1-10 alkyl(oxy)C.sub.1-10 alkyl, --C.sup.1-10 -alkyl(thio)C.sub.1-10 alkyl, --N(R.sup.3)C(O)alkyl, --N(R.sup.3)C(O)alkenyl, --N(R.sup.3)C(O)alkynyl, --N(R.sup.3)C(O)(alkyl)oxy(alkyl), --N(R.sup.3)C(O)(alkyl)thio(alkyl), --N(R.sup.3)C(O)N(alkyl), --N(R.sup.3)C(O)N(alkenyl), --N(R.sup.3)C(O)N(alkynyl), --N(R.sup.3)C(O)N(alkyl)oxy(alkyl), --N(R.sup.3)C(O)N(alkyl)thio(alkyl), --N(R.sup.3)C(O.sub.2)alkyl, --N(R.sup.3)C(O.sub.2)alkenyl, --N(R.sup.3)C(O.sub.2)alkynyl, --N(R.sup.3)C(O.sub.2)(alkyl)oxy(alkyl), --N(R.sup.3)C(O.sub.2)(alkyl)thio(alkyl), --OC(O.sub.2)alkyl, --OC(O.sub.2)alkenyl, --OC(O.sub.2)alkynyl, --OC(O.sub.2)(alkyl)oxy(alkyl), --OC(O.sub.2)(alkyl)thio(alkyl), --N(R.sup.3)C(S)alkyl, --N(R.sup.3)C(S)alkenyl, --N(R.sup.3)C(S)alkynyl, --N(R.sup.3)C(S)(alkyl)oxy(alkyl), --N(R.sup.3)C(S)(alkyl)thio(alkyl), --N(R.sup.3)C(S)N(alkyl), --N(R.sup.3)C(S)N(alkenyl), --N(R.sup.3)C(S)N(alkynyl), --N(R.sup.3)C(S)N(alkyl)oxy(alkyl), --N(R.sup.3)C(S)N(alkyl)thio(alkyl), --N(R.sup.3)C(S)S(alkyl), --N(R.sup.3)C(S)S(alkenyl), --N(R.sup.3)C(S)S(alkynyl), --N(R.sup.3)C(S)S(alkyl)oxy(alkyl), --N(R.sup.3)C(S)S(alkyl)thio(alkyl), --SC(S)S(alkyl), --SC(S)S(alkenyl), --SC(S)S(alkynyl), --SC(S)S(alkyl)oxy(alkyl), and --SC(S)S(alkyl)thio(alkyl);
M is hydrogen, a pharmaceutically acceptable cation, or a metabolically cleavable leaving group;
Y is independently:
(a) hydrogen:
(b) R.sup.1-6, R.sup.8, R.sup.10, --OR.sup.3, --R.sup.11, --OR.sup.12, R.sup.3 S--, R.sup.5 S, R.sup.3 SO--, R.sup.5 SO--, R.sup.3 SO.sub.2 --, R.sup.5 SO.sub.2 --, CF.sub.3 O--, CF.sub.3 S--, CF.sub.3 SO--, --CF.sub.3 SO.sub.2, --OCH.sub.2 oxycyclopropyl, --OCH.sub.2 C(O)OR.sup.3, --OCH.sub.2 OR.sup.3, --OCH.sub.2 C(O)R.sup.3, --OCH.sub.2 C.sub.3-8 -cycloalkyl, --OCH.sub.2 CH(R)R.sup.3, --OCH.sub.2 cyclopropyl, --OCH.sub.2 aryl, --OCH.sub.2 CH(OH)CH.sub.2 OH, aryl-CH.sub.2 --SO.sub.2 --, (R.sup.3).sub.2 CHCH.sub.2 SO.sub.2 --, --CH.sub.2 CH(OH)CH.sub.2 OH, CF.sub.3 SO.sub.2 --, R.sup.3 R.sup.4 N--, --OCH.sub.2 CO.sub.2 R.sup.3, --NR.sup.3 COR.sup.3, --OCONH.sub.2, --OCONR.sup.3 R.sup.4, --CONH.sub.2, --CONR.sup.3 R.sup.4, --CR.sup.3 R.sup.3 R.sup.4, --SO.sub.2 NR.sup.3 R.sup.4, --SONR.sup.3 R.sup.4, --CH.sub.3 OCH.sub.2 NR.sup.3 R.sup.6, --SNR.sup.3 R.sup.4, --CO.sub.2 R.sup.3, --NR.sup.3 R.sup.4 SO.sub.2 R.sup.3, --NR.sup.3 R.sup.4 SOR, --COR.sup.3, CONR.sup.3, --NO.sub.2, --CN, --N(R.sup.5)CONR.sup.3 R.sup.4, --CH.sub.2 N(R.sup.5)CONR.sup.3 R.sup.4, --R.sup.6 NR.sup.3 R.sup.4, --OR.sup.6 NR.sup.3 R.sup.4, --O(O)CR.sup.5, --O(O)CNR.sup.3 R.sup.4, ##STR26## --SR.sup.6 NR.sup.3 R.sup.4, --S(O)R.sup.6 NR.sup.3 R.sup.4, --SO.sub.2 R.sup.6 NR.sup.3 R.sup.4, ##STR27## --SR.sup.6 OH, --S(O)R.sup.6 OH, --SO.sub.2 R.sup.6 OH, --OR.sup.6 OC(O)N(CO.sub.2 R.sup.6)R.sup.6 ;
(c) a heterocycle, including but not limited to, pyridyl, and optionally substituted with a group described in Y section (b);
(d) ##STR28## wherein X' is halo, --C(O) aryl, CF.sub.3, or OR.sup.3, --NR.sub.3 COR.sup.3 ;
--OCONH.sub.2 ;
--CR.sup.3 R.sup.3 R.sup.4 ;
--CH.sub.2 OR.sup.3 ;
--CH.sub.2 OR.sup.3 ;
--CH.sub.2 CO.sub.2 R.sup.3 ;
--CH.sub.2 OCOR.sup.3 ;
R.sup.3 CH(R.sup.3)CH.sub.2 SO.sub.3- ;
--NHCH.sub.2 COOR.sup.3 ;
halo such as F, Cl, Br and I;
N+R.sup.3 R.sup.3 R.sup.4 R.sup.7 ;
--NR.sup.3 SO.sub.2 R.sup.3 ;
COR.sup.3 ;
NO.sub.2 ;
or CN;
or ##STR29## wherein R.sup.13, R.sup.14, and R.sup.15 independently represents:
BO--wherein B is --CH.sub.2 -oxacyclopropyl, --CH.sub.2 OR.sup.3, --CH.sub.2 C(O)R.sup.3, --CH.sub.2 CH(R.sup.3)R.sup.3, --CH.sub.2 Aryl, --CH.sub.2 CH(OH)--CH.sub.2 OH;
R.sup.3 C(R.sup.3).sub.2 CH.sub.2 SO.sub.2 ;
or R.sup.13 -R.sup.14 or R.sup.14 -R.sup.15 are joined together to form a bridge such as --OCHR.sup.2 CHR.sup.2 --S(O).sub.n- wherein n is 0 to 3;
or ##STR30## where X' is halo, --C(O)aryl, --CF.sub.3, or --OR.sup.3 ;
--CH.sub.2 OR.sup.3 ;
--CH.sub.2 CO.sub.2 R.sup.3 ;
--CH.sub.2 COR.sup.3 ;
--NHCH.sub.2 COOR.sup.3 ;
--N+R.sup.3 R.sup.3 R.sup.4 R.sup.7 ;
R.sup.1 and R.sup.2 are independently hydrogen, halogen, or lower alkyl, halo lower alkyl, halo, --COOH;
--CONR.sup.16 R.sup.17 wherein R.sup.16 and R.sup.17 independently represent C.sub.1-6 alkyl and hydrogen, --COOR.sup.3, alkenyl, --COR.sup.3 ;
--CH.sub.2 OR.sup.3 ;
lower alkynyl, CH.sub.2 NR.sup.4 R.sup.3 ;
.dbd.O;
--OR.sup.3 ;
or --NR.sup.3 R.sup.3 ;
R.sup.3 and R.sup.4 are independently cyclic and acyclic alkyl, alkenyl, alkynyl, aryl, aralkyl, alkyaryl, hydrogen, C.sub.1-6 alkoxy--C.sub.1-10 alkyl, C.sub.1-6 alkylthio--C.sub.1-10 alkyl, and C.sub.1-10 substituted alkyl (wherein the substituent is independently hydroxy or carbonyl, located on any of C.sub.1-10);
R.sup.5 is cyclic and acyclic lower alkyl, lower alkenyl, lower alkynyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, aralkyl, or aryl;
R.sup.6 is cyclic and acyclic lower alkyl, lower alkenyl, lower alkynyl, aralkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, or aryl;
R.sup.7 is an organic or inorganic anion;
R.sup.8 is halo alkyl, halo lower alkyl, halo lower alkenyl, halo lower alkynyl, lower alkenyl, lower alkynyl, aralkyl, or aryl;
R.sup.9 is independently hydrogen, halogen, lower alkyl, halo lower alkyl, lower alkenyl, lower alkynyl, --CONR.sup.3 R.sup.4, --COR.sup.5, --CO.sub.2 R.sup.5, --CH.sub.2 OR.sup.5, --CH.sub.2 NR.sup.5 R.sup.5, --CH.sub.2 SR.sup.5, .dbd.O, .dbd.NR.sup.5, --NR.sup.3 R.sup.4, --NR.sup.3 R.sup.4 .sctn.R.sup.7, or --OR.sup.5 ;
and
R.sup.10 is --R.sup.3, --R.sup.8, --C(O)N(OR.sup.3)R.sup.3, --OR.sup.3,
R.sup.11 is C.sub.1 to C.sub.12 alkyl;
substituted C.sub.1 to C.sub.12 alkyl wherein the substituent is selected from the group consisting of hydroxy and amino, alkenyl, lower alkoxy-alkyl;
alkylcarbonylalkyl, -alkylamino, -alkylamino(alkyl or dialkyl), lower alkyl S(O).sub.m -lower alkyl in which m is 0, 1 or 2;
imidazolyl lower alkyl, morpholinyl lower alkyl, thiazolinyl lower alkyl, piperidinyl ower alkyl, imidazolylcarbonyl, morpholinyl carbonyl, amorpholinyl (lower alkyl) aminocarbonyl, N-pyrrylpyridinyl-lower alkyl;
pyridylthio-lower alkyl;
morpholinyl-lower alkyl;
hydroxyphenylthio-lower alkyl;
cyanophenylthio-lower alkyl;
imidazolylthio-lower alkyl;
triazolylthio-lower alkyl;
triazolylphenylthio-lower alkyl;
tetrazolylthio-lower alkyl;
tetrazolylphenylthio-lower alkyl;
aminophenylthio-lower alkyl;
N,N-di-substituted aminophenylthio-lower alkyl wherein the substituents each independently represent lower alkyl;
amidinophenylthio-lower alkyl;
phenylsulfinyl-lower alkyl;
or phenylsulfonyl lower alkyl;
R.sup.12 is selected from the group consisting of:
alkyl;
substituted alkyl wherein the substituent is selected from the group consisting of hydroxy and amino;
-lower alkyl--O--R.sup.18, wherein R.sup.18 is --PO.sub.2 (OH)--M+ or --PO.sub.3 (M+).sub.2, wherein M+ is a pharmaceutically acceptable cation;
--C(O)(CH.sub.2).sub.2 CO.sub.2 --M+, or --SO.sub.3 --M+;
-lower alkylcarbonyl-lower alkyl;
-carboxy lower alkyl;
-lower alkylamino-lower alkyl;
N,N-di-substituted amino lower alkyl-, wherein the substituents each independently represent lower alkyl;
pyridyl-lower alkyl;
imidazolyl-lower alkyl;
imidazolyl-Y-lower alkyl wherein Y is thio or amino;
morpholinyl-lower alkyl;
pyrrolidinyl-lower alkyl;
thiazolinyl-lower alkyl;
piperidinyl-lower alkyl;
morpholinyl-lower hydroxyalkyl;
N-pyrryl;
piperazinyl-lower alkyl;
N-substituted piperazinyl-lower alkyl, wherein the substituent is lower alkyl;
triazolyl-lower alkyl;
tetrazolyl-lower alkyl;
tetrazolylamino-lower alkyl;
or thiazolyl-lower alkyl;
R.sup.19 is H, lower alkyl, or lower alkenyl;
and
R.sup.20 is H, halogen, lower alkoxy, or lower alkyl.

103 more elements

Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase

Life of this patent

Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase

Life of this patent

Abstract

Claims27